Sabrina Serani is a senior editor for Targeted Oncology.
GLS1 With BCL-2 Presents New Treatment Potential in DLBCL
Combining the glutaminase-1 inhibitor CB-839 and BCL-2 inhibitor venetoclax could be a new avenue for the treatment of diffuse large B-cell lymphoma.
FDA Initiates Investigation of CAR T Immunotherapies
The investigation follows reports of T-cell malignancies after treatment with chimeric antigen receptor T-cell immunotherapies.
FDA Clears IND for Tumor Infiltrating Lymphocyte Therapy
A phase 1/2 study of KSQ-001EX will commence at MD Anderson Cancer Center following this investigational new drug approval from the FDA.
Connecting Heart Disease and Hematologic Malignancies
A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.
FDA Grants FTD to Olvi-Vec in Ovarian Cancer Subgroup
Olvimulogene nanivacirepvec, an oncolytic viral-based therapy, has earned a fast track designation from the FDA in ovarian cancer resistant or refractory to platinum-based chemotherapy.
Belantamab Mafodotin Plus BorDex Improves PFS in RRMM
The phase 3 DREAMM-7 trial met its primary end point of progression-free survival, and overall survival data is trending positively.
FDA Grants Epcoritamab Breakthrough Drug Designation for FL
The FDA breakthrough drug designation for epcoritamab in follicular lymphoma was supported by findings from the phase 1/2 EPCORE NHL-1 study.
Forging a Treatment Path for Multiple Myeloma With ASCT
Steady-state and chemotherapy-based mobilization both demonstrate feasibility in stem cell collection for patients with multiple myeloma undergoing autologous stem cell transplants, but challenges remain.
New Treatment Pathways for CD73-Expressing Tumors
In an interview with Targeted Oncology, Jeff Stein, PhD, discussed the challenges and prospects of CD73-targeting agents.
New Phase 1 Findings Show Promise of Cancer Vaccines in KRAS Mutations
In an interview with Targeted Oncology, Chris Haqq, MD, PhD, discussed the potential use of cancer vaccines in patients with KRAS-mutated pancreatic and colon cancer.
Behind the FDA Approval of Enzalutamide for Prostate Cancer
Neal Shore, MD, FACS, discussed the phase 3 EMBARK trial and what the FDA approval of enzalutamide means for the prostate cancer treatment landscape.
Plixorafenib Delivers Promising Outcomes in CNS Tumors
Results from a phase 1/2a trial showed that plixorafenib had potential regarding safety and efficacy in BRAF-mutated solid tumors, especially in primary central nervous system tumors.
Olaptesed Pegol Delivers Promising Survival Data in GBM
The combination of olaptesed pegol, bevacizumab, and radiotherapy showed an improvement in overall survival among patients with glioblastoma, according to findings from a phase 1/2 study.
PARP Inhibitors in mCRPC Linked to High Risk of Hematological AEs
The use of poly ADP ribose polymerase inhibitors in the treatment of metastatic castration-resistant prostate cancer were associated with an increased risk of hematological adverse events.
FDA OKs Enzalutamide for Nonmetastatic Castration-Sensitive Prostate Cancer
Enzalutamide is the first and only androgen receptor signaling inhibitor approved by the FDA in this intent-to-treat population.
FDA Approves Pembrolizumab/Chemo for Gastric and GEJ Adenocarcinoma
Pembrolizumab and fluoropyrimidine- and platinum-containing chemotherapy are now FDA-approved for the treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
FDA’s ODAC Confronts Issues With Accelerated Approval Program
The FDA’s Oncologic Drugs Advisory Committee discussed delays that can occur when drugs are granted accelerated approval, and the post-approval confirmatory trials of pralatrexate and belinostat for peripheral T-cell lymphoma.
Durvalumab/CRT Misses Primary End Point in NSCLC
In a phase 3 trial, concurrently administered durvalumab and platinum-based chemoradiotherapy did not increase progression-free survival in stage III unresectable non–small cell lung cancer.
Novel Treatment Shows Safety/Tolerability in Ovarian Cancer
The combination of tumor-infiltrating lymphocytes and chemotherapy showed a robust response rate and improvements in progression-free survival in a phase 1/2 study.
ENB-003 Data Shows Promise in Platinum-Resistant Ovarian Cancer
Findings from a phase 1 trial shows the early promise of an ENB-003 and pembrolizumab regimen for the treatment of platinum refractory or resistant ovarian cancer.
FDA OKs PD-L1 pharmDx for Gastric and GEJ Cancer
This companion diagnostic tool, which is already approved for use in 5 other cancer types, identifies patients who may be suited for treatment with pembrolizumab.
Predicting Patient Outcomes in CLL
A recent study found that CXC chemokine ligand 13 and galectin-9 could be prognostic biomarkers of progression-free survival and treatment response in patients with chronic lymphocytic leukemia.
Favorable Safety/Efficacy Seen With RP2 in Uveal Melanoma
RP2 demonstrated promising response rates and tolerability in the treatment of metastatic uveal melanoma, both as a monotherapy and in combination with nivolumab.
PDS0101, PDS0301, and Bintrafusp Alfa Enhances Survival in HPV+ Cancers
The combination of and investigational immune checkpoint inhibitor, immunotherapy, and antibody-drug conjugate showed improvements in overall survival in patients with a variety of human papillomavirus-positive cancers.
FDA Grants Orphan Drug Designation to THIO for Glioblastoma
THIO has received 2 prior orphan drug designations, and the agent has shown promise in preclinical studies for the treatment of glioblastoma.
BXCL701 Plus Pembrolizumab Improves OS in mCRPC
In patients with metastatic castration-resistant prostate cancer of the adenocarcinoma phenotype, the combination of BXCL701 and pembrolizumab led to a median overall survival of 15.5 months.
FDA Restricts Pembro/Chemo Use for Gastric Cancer
The updated indication limits the use of pembrolizumab and chemotherapy to tumors expressing PD-L1 as determined by an FDA-approved test.
SRK-181/Pembro Combination Shows Promise in ccRCC
The combination of SRK-181 and pembrolizumab demonstrated improvements in objective response rate among patients with clear cell renal cell carcinoma in a phase 1 proof-of-concept study.
PFS Improvements Seen With Selinexor in Endometrial Cancer Subgroup
Selinexor maintenance therapy shows potential in bettering survival compared with placebo in patients with TP53 wild-type recurrent or advanced endometrial cancer.
Avutometinib/Defactinib Betters ORR in Recurrent Ovarian Cancer
Findings from the phase 2 RAMP 201 trial show avutometinib plus defactinib demonstrates robust efficacy in patients with recurrent low-grade serious ovarian cancer.
2 Clarke Drive Cranbury, NJ 08512